Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Cediranib, Paclitaxel, and Carboplatin in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

This study has been completed.
Information provided by (Responsible Party):
Canadian Cancer Trials Group ( NCIC Clinical Trials Group ) Identifier:
First received: November 20, 2008
Last updated: November 18, 2015
Last verified: June 2015

RATIONALE: Cediranib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether cediranib is more effective than a placebo when given together with paclitaxel and carboplatin in treating patients with non-small cell lung cancer.

PURPOSE: This randomized phase III trial is studying how well cediranib works when given together with paclitaxel and carboplatin in treating patients with stage IIIB or stage IV non-small cell lung cancer.

Condition Intervention Phase
Lung Cancer
Drug: carboplatin
Drug: cediranib maleate
Drug: paclitaxel
Other: placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Double Blind Randomized Trial of Cediranib Versus Placebo in Patients Receiving Paclitaxel/Carboplatin Chemotherapy for the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer

Resource links provided by NLM:

Further study details as provided by Canadian Cancer Trials Group ( NCIC Clinical Trials Group ):

Primary Outcome Measures:
  • Overall Survival [ Time Frame: at every 3 months visit throughout trial, a median of 13.1 months. ]
    Medians of survival time, and their confidence intervals.

Secondary Outcome Measures:
  • Progression-free Survival [ Time Frame: at every 3 months visit throughout trial, a median of 12 months ]
    Medians of PFS and their confidence intervals by arm

  • Objective Tumor Response as Assessed by RECIST Criteria v1.1. [ Time Frame: Every 6 weeks at the end of every 2 cycles during protocol treatment and every 12 weeks after protocol treatment until progression. ]
    Every 6 weeks at the end of every 2 cycles during protocol treatment and every 12 weeks after protocol treatment until progression.

Enrollment: 306
Study Start Date: November 2008
Study Completion Date: January 2014
Primary Completion Date: June 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Arm I Cediranib
Patients receive oral cediranib once daily on days 1-21 and paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1.
Drug: carboplatin
Given IV
Drug: cediranib maleate
Given orally
Drug: paclitaxel
Given IV
Placebo Comparator: Arm II Placebo
Patients receive oral placebo once daily on days 1-21 and paclitaxel and carboplatin as in arm I.
Drug: carboplatin
Given IV
Drug: paclitaxel
Given IV
Other: placebo
Given orally

Detailed Description:



  • To compare overall survival of patients with stage IIIB-IV non-small cell lung cancer treated with cediranib vs placebo administered in combination with paclitaxel and carboplatin.


  • To compare the progression-free survival of patients treated with these regimens.
  • To compare the objective response rates in patients treated with these regimens.
  • To estimate time to response and response duration in patients treated with these regimens.
  • To evaluate the nature, severity, and frequency of toxicities, including hemorrhage and hemoptysis, in patients treated with these regimens.
  • To compare the pharmacokinetics of paclitaxel between the two arms in a subset of enrolled patients
  • To compare the quality of life of patients treated with these regimens.
  • To determine the incremental cost effectiveness and cost utility ratios for these regimens.
  • To correlate the expression of tissue markers (at diagnosis) with outcomes and response in an exploratory fashion OUTLINE: This is a multicenter study. Patients are stratified by gender, center, disease stage (IIIB vs IV), weight loss (< 5% vs 5-10% vs unknown), and prior adjuvant chemotherapy (yes vs no). Patients are randomized to 1 of 2 treatment arms.
  • Arm I: Patients receive oral cediranib once daily on days 1-21 and paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1.
  • Arm II: Patients receive oral placebo once daily on days 1-21 and paclitaxel and carboplatin as in arm I.

Treatment in both arms repeats every 21 days for 4 to 6 courses in the absence of disease progression or unacceptable toxicity.

Quality of life is assessed at baseline, on day 1 of each course, and periodically thereafter.

After completion of study therapy, patients are followed every 12 weeks.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Histologically or cytologically* confirmed non-small cell carcinoma of the lung

    • Stage IIIB or IV disease NOTE: *Diagnosis by sputum cytology alone allowed provided it is confirmed by a second sputum specimen
  • Measurable disease, defined as at least 1 measurable lesion > 20 mm by x-ray, ultrasound, or physical exam or ≥ 10 mm (lymph nodes must be ≥ 15 mm in the short axis) by spiral CT scan or physical exam (in the first 260 patients randomized**)

    • Measurable lesions that are sole sites of disease must be outside a previous radiotherapy field unless disease progression has been documented NOTE: **Measurable or nonmeasurable disease allowed after the first 260 patients
  • No appreciable cavitation in central thoracic lesions
  • No untreated brain or meningeal metastases

    • Patients with treated and radiologic or clinical evidence of stable brain metastases, with no evidence of cavitation or hemorrhage in the brain lesion, are eligible provided the metastases are asymptomatic and do not require corticosteroids
  • No pleural effusion


  • ECOG performance status 0-1
  • Absolute granulocyte count ≥ 1,500/mm^3
  • Platelet count ≥ 100,000/mm^3
  • Creatinine clearance > 50 mL/min
  • Total bilirubin ≤ 1.5 times upper limit of normal (ULN)
  • ALT ≤ 2 times ULN (< 5 times ULN if due to liver metastasis)
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective double-method contraception (barrier method for men)
  • No other malignancy within the past 5 years, except in situ cancer, basal cell or squamous cell skin cancer, or malignancy cured by definitive prior therapy alone (e.g., surgery) and continuously disease-free for at least 5 years
  • Mean QTc with Bazett correction ≤ 480 msec in screening ECG (at least one value must be ≤ 480 msec when measured automatically or manually corrected using Bazett's or Fridericia's correction)
  • No history of familial long QT syndrome
  • No untreated and/or uncontrolled cardiovascular conditions and/or symptomatic cardiac dysfunction including any of the following:

    • Unstable angina
    • Congestive heart failure
    • Myocardial infarction within the past year
    • Cardiac ventricular arrhythmias requiring medication
    • History of second or third degree atrioventricular conduction defects
  • LVEF > 50% in patients with significant cardiac history, even if controlled
  • No resting BP consistently > 150 mm Hg systolic and/or > 100 mm Hg diastolic
  • No poorly controlled hypertension
  • No history of labile hypertension or poor compliance with anti-hypertensive medication
  • No overt bleeding (> 30 mL bleeding/episode) from any site within the past 3 months
  • No clinically relevant hemoptysis (> 5 mL fresh blood) within the past 4 weeks

    • Flecks of blood in sputum allowed
  • No active or uncontrolled infections, or serious illnesses or medical conditions which would not permit the patient to be treated according to the study
  • No prior allergic reactions to drugs containing Cremophor EL®
  • No inflammatory bowel disease (e.g., Crohn disease or ulcerative colitis)
  • No documented weight loss > 10% within the past 3 months

    • Patients with weight loss 5-10% or whose weight loss status is unknown are eligible provided serum albumin levels are ≥ 30 g/L
  • No peripheral neuropathy > grade 1
  • Must be fit for combined modality treatment
  • Sufficiently fluent and willing to complete quality-of-life questionnaires


  • See Disease Characteristics
  • Recovered from all prior therapy
  • No prior chemotherapy for metastatic or recurrent disease
  • No prior anti-angiogenic therapy (e.g., bevacizumab, cediranib, AZD6474, PTK/ZK, sunitinib malate, or other agents considered angiogenesis inhibitors by NCIC Clinical Trials Group for any indication)

    • Prior cox-2 inhibitors in standard doses allowed
  • At least 12 months since prior adjuvant chemotherapy for completely resected disease

    • Combined chemotherapy/radiotherapy regimens for locally advanced stage IIIB disease not allowed
  • At least 21 days since prior radiotherapy
  • At least 21 days since prior cetuximab or other monoclonal antibodies
  • At least 14 days since prior EGFR inhibitor therapy for adjuvant therapy or metastatic disease (e.g., tyrosine kinase inhibitors, vaccines, or other agents considered by NCIC CTG as acting on the EGFR pathway)
  • At least 14 days since prior major surgery
  • At least 1 week since prior corticosteroids
  • No other concurrent experimental drugs, anticancer treatment, or investigational therapy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00795340

Instituto Nacional de Cancer (INCA)
Rio de Janeiro, Brazil, CEP20231-050
Instituto de Cancer Arnaldo Vieira de Carvalho
Sao Paulo, Brazil, 01224-010
Canada, Alberta
Tom Baker Cancer Centre
Calgary, Alberta, Canada, T2N 4N2
Cross Cancer Institute
Edmonton, Alberta, Canada, T6G 1Z2
Canada, British Columbia
BCCA - Abbotsford Centre
Abbotsford, British Columbia, Canada, V2S 0C2
BCCA - Fraser Valley Cancer Centre
Surrey, British Columbia, Canada, V3V 1Z2
BCCA - Vancouver Cancer Centre
Vancouver, British Columbia, Canada, V5Z 4E6
Canada, Ontario
Juravinski Cancer Centre at Hamilton Health Sciences
Hamilton, Ontario, Canada, L8V 5C2
Cancer Centre of Southeastern Ontario at Kingston
Kingston, Ontario, Canada, K7L 5P9
London Regional Cancer Program
London, Ontario, Canada, N6A 4L6
Ottawa Health Research Institute - General Division
Ottawa, Ontario, Canada, K1H 8L6
Algoma District Cancer Program
Sault Ste. Marie, Ontario, Canada, P6B 0A8
Niagara Health System
St. Catharines, Ontario, Canada, L2R 7C6
Mount Sinai Hospital
Toronto, Ontario, Canada, M5G 1X5
Univ. Health Network-Princess Margaret Hospital
Toronto, Ontario, Canada, M5G 2M9
Windsor Regional Cancer Centre
Windsor, Ontario, Canada, N8W 2X3
Canada, Quebec
McGill University - Dept. Oncology
Montreal, Quebec, Canada, H2W 1S6
Canada, Saskatchewan
Allan Blair Cancer Centre
Regina, Saskatchewan, Canada, S4T 7T1
University Institute of Cardiology and
Quebec, Canada, G1V 4G5
Sponsors and Collaborators
NCIC Clinical Trials Group
Study Chair: Scott A. Laurie, MD, FRCPC Ottawa Regional Cancer Centre
  More Information

Responsible Party: NCIC Clinical Trials Group Identifier: NCT00795340     History of Changes
Other Study ID Numbers: BR29
CDR0000618671 ( Other Identifier: PDQ )
Study First Received: November 20, 2008
Results First Received: April 28, 2015
Last Updated: November 18, 2015

Keywords provided by Canadian Cancer Trials Group ( NCIC Clinical Trials Group ):
stage IIIB non-small cell lung cancer
stage IV non-small cell lung cancer
recurrent non-small cell lung cancer

Additional relevant MeSH terms:
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Albumin-Bound Paclitaxel
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Protein Kinase Inhibitors
Enzyme Inhibitors processed this record on May 25, 2017